Durvalumab

In this article, we will discuss Durvalumab (Dosage Overview). So, let’s get started.

Indications

Urothelial Carcinoma

Durvalumab is indicated for the treatment of patients with locally advanced or metastatic urothelial
carcinoma who:
• have disease progression during or following platinum-containing chemotherapy.
• have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Non-Small Cell Lung Cancer

Durvalumab is indicated for the treatment of patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

Dosage

Recommended Dosage for Urothelial Carcinoma

The recommended dose of Durvalumab is 10 mg/kg administered as an intravenous infusion over 60 minutes every 2 weeks, until disease progression or unacceptable toxicity.

Recommended Dosage for NSCLC

The recommended dose of Durvalumab is 10 mg/kg administered as an intravenous infusion over 60 minutes every 2 weeks until disease progression, unacceptable toxicity, or a maximum of 12 months.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.